Literature DB >> 6826104

Relapse of antibiotic associated colitis: endogenous persistence of Clostridium difficile during vancomycin therapy.

B A Walters, R Roberts, R Stafford, E Seneviratne.   

Abstract

This study reports 24 patients with antibiotic associated colitis due to Clostridium difficile. Fifteen patients were treated with vancomycin due to the severity of the colitis and in eight of these a clinical relapse of the colitis occurred after vancomycin therapy was stopped. Bacteriological investigations of these patients indicated that C difficile was able to persist in stool samples during vancomycin therapy in the absence of detectable cytotoxin. This was in contrast with the seven patients successfully treated with vancomycin without relapse, and those not treated with vancomycin where both stool cultures and cytotoxin assays became negative. These results suggest that patients being treated with vancomycin for antibiotic associated colitis due to C difficile should have stool cultures done during and after treatment. Persistence of the organism in the absence of detectable cytotoxin may identify those patients who relapse and lead to either recommencement of vancomycin or alternative therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6826104      PMCID: PMC1419935          DOI: 10.1136/gut.24.3.206

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  21 in total

1.  Outbreak of clindamycin-associated colitis.

Authors:  S A Kabins; T J Spira
Journal:  Ann Intern Med       Date:  1975-12       Impact factor: 25.391

2.  Clostridium difficile: isolation and characteristics.

Authors:  S Hafiz; C L Oakley
Journal:  J Med Microbiol       Date:  1976-05       Impact factor: 2.472

3.  Modified broth-disk method for testing the antibiotic susceptibility of anaerobic bacteria.

Authors:  T D Wilkins; T Thiel
Journal:  Antimicrob Agents Chemother       Date:  1973-03       Impact factor: 5.191

4.  Pseudomembranous colitis.

Authors:  M R Keighley; D W Burdon; G A Mogg; R H George; J Alexander-Williams; H Thompson
Journal:  Lancet       Date:  1979-03-10       Impact factor: 79.321

5.  Oral vancomycin for antibiotic-associated pseudomembranous colitis.

Authors:  F Tedesco; R Markham; M Gurwith; D Christie; J G Bartlett
Journal:  Lancet       Date:  1978-07-29       Impact factor: 79.321

6.  Treatment of antibiotic-induced colitis by metronidazole.

Authors:  H T Dinh; S Kernbaum; J Frottier
Journal:  Lancet       Date:  1978-02-11       Impact factor: 79.321

7.  Vancomycin for antibiotic-induced colitis.

Authors:  R Modigliani; J C Delchier
Journal:  Lancet       Date:  1978-01-14       Impact factor: 79.321

8.  Treatment of antibiotic-associated pseudomembranous colitis with cholestyramine resin.

Authors:  E W Kreutzer; F D Milligan
Journal:  Johns Hopkins Med J       Date:  1978-09

9.  Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea.

Authors:  M R Keighley; D W Burdon; Y Arabi; J A Williams; H Thompson; D Youngs; M Johnson; S Bentley; R H George; G A Mogg
Journal:  Br Med J       Date:  1978-12-16

10.  Selective and differential medium for isolation of Clostridium difficile.

Authors:  W L George; V L Sutter; D Citron; S M Finegold
Journal:  J Clin Microbiol       Date:  1979-02       Impact factor: 5.948

View more
  26 in total

1.  Successful use of nitazoxanide in the treatment of recurrent Clostridium difficile infection.

Authors:  Fnu Rafiullah; Sunil Kanwal; Usman M Majeed; Mark A Korsten; Faisal H Cheema; Munish Luthra; Muhammad Rizwan Sohail
Journal:  BMJ Case Rep       Date:  2011-11-21

Review 2.  Pathogenesis and treatment of Clostridium difficile infection.

Authors:  I Tonna; P D Welsby
Journal:  Postgrad Med J       Date:  2005-06       Impact factor: 2.401

3.  Pleiotropic role of the RNA chaperone protein Hfq in the human pathogen Clostridium difficile.

Authors:  P Boudry; C Gracia; M Monot; J Caillet; L Saujet; E Hajnsdorf; B Dupuy; I Martin-Verstraete; O Soutourina
Journal:  J Bacteriol       Date:  2014-06-30       Impact factor: 3.490

4.  The key sigma factor of transition phase, SigH, controls sporulation, metabolism, and virulence factor expression in Clostridium difficile.

Authors:  Laure Saujet; Marc Monot; Bruno Dupuy; Olga Soutourina; Isabelle Martin-Verstraete
Journal:  J Bacteriol       Date:  2011-05-13       Impact factor: 3.490

5.  gyrA and gyrB mutations are implicated in cross-resistance to Ciprofloxacin and moxifloxacin in Clostridium difficile.

Authors:  Larbi Dridi; Jacques Tankovic; Béatrice Burghoffer; Frédéric Barbut; Jean-Claude Petit
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

6.  Clostridium difficile associated diarrhoea in hospitalised patients: onset in the community and hospital and role of flexible sigmoidoscopy.

Authors:  S S Johal; J Hammond; K Solomon; P D James; Y R Mahida
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

7.  Characterization of the sporulation initiation pathway of Clostridium difficile and its role in toxin production.

Authors:  Sarah Underwood; Shuang Guan; Vinod Vijayasubhash; Simon D Baines; Luke Graham; Richard J Lewis; Mark H Wilcox; Keith Stephenson
Journal:  J Bacteriol       Date:  2009-09-25       Impact factor: 3.490

Review 8.  Clostridium difficile infection: a common clinical problem for the general internist.

Authors:  G M Caputo; M R Weitekamp; A E Bacon; C Whitener
Journal:  J Gen Intern Med       Date:  1994-09       Impact factor: 5.128

9.  Relapse versus reinfection with Clostridium difficile.

Authors:  G L O'Neill; M H Beaman; T V Riley
Journal:  Epidemiol Infect       Date:  1991-12       Impact factor: 2.451

10.  Suppression by Saccharomyces boulardii of toxigenic Clostridium difficile overgrowth after vancomycin treatment in hamsters.

Authors:  G W Elmer; L V McFarland
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.